World Health Organization site
Skip Navigation Links

Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Last refreshed on: 16 December 2017
Main ID:  NCT02426905
Date of registration: 18/09/2014
Prospective Registration: Yes
Primary sponsor: Univar BV
Public title: Study to Assess Long-Term Outcomes of Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
Scientific title: Multicentre, Retrospective and Prospective Study to Assess Long-Term Outcomes of Chelator-Based Treatment With Trientine in Wilson Disease Patients Withdrawn From Therapy With d-Penicillamine
Date of first enrolment: January 2016
Target sample size: 90
Recruitment status: Active, not recruiting
Study type:  Interventional
Study design:  Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).  
Phase:  Phase 4
Countries of recruitment
Germany Greece Italy United Kingdom
Name:     Karl-Heinz Weiss, MD
Affiliation:  Universit√§tsklinik Heidelberg
Key inclusion & exclusion criteria

Inclusion Criteria:

- Patients aged 1 year to 90 years of age.

- Physician established diagnosis of Wilson disease based on a Ferenci score > 3.

- Documented treatment with d-Penicillamine, withdrawal of treatment with d-
Penicillamine, followed by treatment with trientine for at least 6 months at date of
informed consent.

- Able/willing to provide written informed consent.

- For enrolment in the prospective part, enrolment in the retrospective part of the
study is required.

Exclusion Criteria:

- Incomplete history of medication use for trientine from initial diagnosis to latest
follow up.

- Unavailable outcome data for hepatic and neurological course of disease at assessment
time points.

- Patients with acute liver failure and fulminant hepatic disease with fatal outcome.

- Hypersensitivity to trientine and severe anaemia.

Age minimum: 1 Year
Age maximum: 90 Years
Gender: All
Health Condition(s) or Problem(s) studied
Wilson Disease
Drug: trientine dihydrochloride
Primary Outcome(s)
Clinical outcome specific to the prospective part of the study [Time Frame: 12 months]
Clinical outcome specific to the retrospective part of the study [Time Frame: 48 months]
Secondary Outcome(s)
Quality of Life Endpoints for the Prospective Part of the Study [Time Frame: 12 months]
Safety Endpoint Applicable to both the Retrospective and Prospective Parts of the Study [Time Frame: Up to 60 months]
Secondary ID(s)
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Ethics review
Results available:
Date Posted:
Date Completed:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history